Nurse Practitioner in Aledo, IL Accepting Medicare
6 Nurse Practitioner nurses found. Showing 1 - 6
 Mrs. Lindsay Marie Chick, ARNP Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 1007 Nw 3rd St, Aledo, IL 61231 Phone: 309-582-9450 |
 Jesse George Korns, Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 1007 Nw 3rd St, Aledo, IL 61231 Phone: 309-582-9450 |
Morgan L Ryan, APN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 1007 Nw 3rd St, Aledo, IL 61231 Phone: 563-355-9200 Fax: 563-355-3419 |
Chantelle Evonne Peterson, APN Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 1007 Nw 3rd St, Aledo, IL 61231 Phone: 309-582-9450 |
Megan Nache, APN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 1007 Nw 3rd St, Aledo, IL 61231 Phone: 309-582-3789 Fax: 309-582-3735 |
Amy L Feist, A.P.N Nurse Practitioner - Acute Care Medicare: Accepting Medicare Assignments Practice Location: 1007 Nw 3rd St, Aledo, IL 61231 Phone: 309-309-5829 Fax: 309-582-9479 |
News Archive
Study shows possibility of using PET imaging to manage chronic liver diseases
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications. These effects may soon be a thing of the past for some patients thanks to new research showing PET imaging with the 18F-FAC radiotracer can be used as a non-invasive substitute. The study is featured in the October issue of The Journal of Nuclear Medicine.
Temperature-sensitive nanoparticle boosts drug antitumor activity
Using temperature-sensitive, lipid- and polymer-based nanoparticles with a polymer coating, researchers in Korea have created an anticancer drug delivery vehicle that may provide a significant boost to the therapeutic efficacy of anticancer agents, particularly when used in conjunction with hyperthermia.
Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm
Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic's proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.
Threat to the ACA turns up the heat on attorney general races
For years, congressional Republicans have vowed to repeal the Affordable Care Act. Now, in a case sending shock waves through midterm election campaigns, Republican attorneys general across the country may be poised to make good on that promise.
› Verified 9 days ago